胰腺神经内分泌肿瘤的治疗

摘要/Abstract

中图分类号:

R735.9

张俊, 姜毓, 沈柏用. 胰腺神经内分泌肿瘤的治疗[J]. 外科理论与实践, 2019, 24(03): 208-211.

[1] Partelli S, Javed AA, Andreasi V, et al.The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms[J]. Eur J Surg Oncol,2018,44(6):778-783.
[2] Fairweather M, Swanson R, Wang J, et al.Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database[J]. Ann Surg Oncol,2017,24(8):2319-2325.
[3] Hüttner FJ, Schneider L, Tarantino I, et al.Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis[J]. Langenbecks Arch Surg,2015,400(6):715-723.
[4] Le Treut YP, Grégoire E, Klempnauer J, et al.Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study[J]. Ann Surg,2013, 257(5):807-815.
[5] Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site[J]. Neuroendocrinology,2016,103(2):172-185.
[6] Cives M, Strosberg J.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors[J]. Drugs,2015,75(8):847-858.
[7] Rinke A, Müller HH, Schade-Brittinger C, et al.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol,2009,27(28):4656-4663.
[8] Wang Y, Wang W, Jin K, et al.Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors[J]. Oncol Lett,2017,13(3):1165-1174.
[9] Caplin ME, Pavel M, Ćwikła JB, et al.Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med,2014,371(3):224-233.
[10] Scarpa A, Chang DK, Nones K, et al.Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature,2017,543(7643):65-71.
[11] Yao JC, Shah MH, Ito T, et al.Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med,2011, 364(6):514-523.
[12] Raymond E, Dahan L, Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med,2011,364(6):501-513.
[13] Sorbye H, Welin S, Langer SW, et al.Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma(WHO G3): the NORDIC NEC study[J]. Ann Oncol,2013,24(1):152-160.
[14] Strosberg J, El-Haddad G, Wolin E, et al.Phase 3 trial of¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors[J]. N Engl J Med,2017,376(2):125-135.
[15] Vanderwalde A, Spetzler D, Xiao N, et al.Microsatellite instability status determined by next-generation sequen-cing and compared with PD-L1 and tumor mutational bur-den in 11,348 patients[J]. Cancer Med,2018,7(3):746-756.

胰腺神经内分泌肿瘤的治疗

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价

[1]	邢颖, 程石.胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114.
[2]	王远江, 邹浩.胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[3]	赵法之, 赵平.胃癌治疗手术中心论体系的形成与完善[J]. 外科理论与实践, 2023, 28(01): 24-30.
[4]	王杰强综述, 马德奎审校.Trop2基因与三阴性乳腺癌的研究进展[J]. 外科理论与实践, 2022, 27(05): 473-477.
[5]	程威, 黄雨桦, 王剑, 李幼生.影响癌性肠梗阻病人预后的多因素分析[J]. 外科理论与实践, 2022, 27(04): 340-345.
[6]	李佳, 吕良敬.靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[7]	王贵福, 刘仁杰, 柏斗胜, 蒋国庆, 张弛, 王谦, 王翱卿, 金圣杰.胆石性肠梗阻的诊断与治疗[J]. 外科理论与实践, 2022, 27(02): 169-172.
[8]	顾伟孙骏李志强卫晓恩.高活动状态老年人桡骨远端骨折功能预后的影响因素[J]. 组织工程与重建外科杂志, 2021, 17(5): 405-.
[9]	黄乃思, 陈嘉莹, 嵇庆海, 王宇.靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践, 2021, 26(06): 493-496.
[10]	常宇宸, 宋陆茜.B细胞淋巴瘤2抑制剂在髓系肿瘤治疗中的机制研究及应用进展[J]. 内科理论与实践, 2021, 16(04): 272-275.
[11]	冯秀娟, 吴涛, 白海.急性髓系白血病DNA异常甲基化及治疗进展[J]. 内科理论与实践, 2021, 16(04): 282-286.
[12]	刘泓源, 杨希, 顾豪, 胡丽, 孙怡, 陈辉, 林晓曦.1例复杂静脉畸形的靶向治疗[J]. 组织工程与重建外科杂志, 2020, 16(3): 198-200.
[13]	刘泓源, 葛同鑫, 林晓曦.静脉/淋巴管畸形靶向治疗的研究进展[J]. 组织工程与重建外科杂志, 2020, 16(3): 204-209.
[14]	缪嘉颖, 董继英, 姚敏, 李青峰.瘢痕色素脱失的研究进展[J]. 组织工程与重建外科杂志, 2020, 16(2): 165-167.
[15]	钱梨寒, 沈柏用.局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446.